MFDS approves CJ HealthCare’s acid reflux treatment ‘K-Cab Tab’ as new drug

Published: 2018-07-09 17:40:34

Updated: 2018-07-09 17:40:34

CJ HealthCare;s acid reflux treatment ‘K-Cab Tab’ acquired approval as a Korean new drug.

The Ministry of Food and Drug Safety(MFDS) acquired approval of CJ HealthCare’s acid reflux treatment ‘K-Cab Tab 50mg(generic name: tegoprazan)’ as a Korean new drug on 5 July.

Indications of the drug approved from the MFDS are the treatments of erosive acid reflux and non-erosive acid reflux.

K-Cap Tab...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.